SCHEMBL1698640

SCHEMBL1698640

CCN1C(C)(C)CC(Oc2ccc(C(=O)O)nc2)CC1(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 4/20 0.55
FLT3 P36888 4/20 0.55
PDGFRB P09619 3/20 0.55
KIT P10721 3/20 0.55
PDGFRA P16234 3/20 0.55
P4HTM Q9NXG6 6/20 0.42
KDM4E B2RXH2 3/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
KMT2A Q03164 2/20 0.37
HIF1A Q16665 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
GLA P06280 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1698633 0.86 CSF1R (0.53) CSF1RFLT3PDGFRBKITPDGFRA
SCHEMBL1698758 0.80 CSF1R (0.52) CSF1RFLT3PDGFRBKITPDGFRA
SCHEMBL31547061 0.75 KDM4E (0.53) P4HTMKDM4EL3MBTL1KMT2AHIF1A
SCHEMBL10328687 0.75 KDM4E (0.53) P4HTMKDM4EL3MBTL1KMT2AHIF1A
SCHEMBL14166822 0.73 KDM4E (0.58) P4HTMKDM4EL3MBTL1KMT2AHIF1A
SCHEMBL10328691 0.73 KDM4E (0.54) P4HTMKDM4EL3MBTL1KMT2AHIF1A
SCHEMBL12525671 0.73 P4HTM (0.49) P4HTMKDM4EL3MBTL1KMT2AHIF1A
SCHEMBL22582826 0.73 SMN1; SMN2 (0.47) P4HTMKDM4EL3MBTL1KMT2AHIF1A
SCHEMBL1698753 0.73 FLT3 (1.00) CSF1RFLT3PDGFRBKITPDGFRA
SCHEMBL29753275 0.71 CSF1R (0.51) CSF1RFLT3PDGFRBKITPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130310357-A1 Azolyl Urea Compounds and Methods of Use Thereof AMBIT BIOSCIENCES CORPORATION (US) 2013-11-21 US claimed
US-9296722-B2 Azolyl urea compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION (US) 2016-03-29 US disclosed
US-20130310357-A1 Azolyl Urea Compounds and Methods of Use Thereof AMBIT BIOSCIENCES CORPORATION (US) 2013-11-21 US disclosed
WO-2011150198-A1 AZOLYL UREA COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2011-12-01 WO disclosed
WO-2011150201-A2 AZOLYL AMIDE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2011-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310357-A1 Azolyl Urea Compounds and Methods of Use Thereof CSF1R, CSF3R, ARG1 CSF1R 1/4885FLT3 4/4885PDGFRB 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.